Pharmacy & Biological SciencesCategory
All 10 regions ranked have significant assets that make them attractive to biopharma researchers, executives, and investors.
Recent lawsuits are asking courts whether the current crisis is comparable to the one over tobacco in the ’90s.
For years, clinics across the country have been offering experimental stem cell therapies, but no state has given them legal validation—yet.
The FDA can’t regulate drug prices, but it can implement measures aimed at deterring the types of price hikes that have made so many headlines over more than a year.
How a proposed tax penalty on drugs with price increases exceeding the inflation could impact patients, public insurance programs, and innovation.
Researchers found nearly a third of approvals from 2001 through 2010 had major safety issues years after they were widely available to patients.
Managing post-op pain is a team effort—and who better to lead the team than a medication expert?
The arrival of Radicava for ALS marks the first new drug in the market for this rare disease since 1995.
Congress grants the National Institutes of Health a $2 billion raise.
The incidence of diabetes is 17% higher in rural areas than it is in cities.